• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bio-Rad launches COVID-19 assay

April 7, 2020 By Danielle Kirsh

Bio-Rad Laboratories to acquire RainDance TechnologiesBio-Rad Laboratories (NYSE:BIO) today said it is launching is blood-based immunoassay kit to identify COVID-19 antibodies.

The assay is currently undergoing clinical evaluation in several hospitals, but 700 samples of data have shown specificity above 99%.

After being infected with SARS-CoV-2, viral antigens stimulate the immune system to produce antibodies and fight the virus. Bio-Rad suggests the blood-based immunoassay kit can help clinicians determine if an individual has been infected by the virus and developed an immune response.

“Using a serology test to support the diagnosis of COVID-19 and to screen populations can provide a more complete understanding of infection rates as well as immunity,” clinical diagnostics executive VP and president Dara Wright said in a news release. “The detection of antibodies to SARS-CoV-2 on a large scale may be used to guide public authorities in their decisions to lift partial or total containment orders according to the serological status of the population. Molecular and serology testing are highly complementary in this regard.”

Bio-Rad’s immunoassay kit can detect total immunoglobulin and is designed for manual use or on an automated immunoassay platform like the company’s Evolis System.

The company plans to offer the immunoassay kit globally and plans to use the FDA’s emergency use authorization process to expedite U.S. availability.

Filed Under: Clinical Trials, Diagnostics Tagged With: Bio-Rad Laboratories

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS